ERBB2 and breast carcinoma: A hyperactive PI3K/AKT/mTOR pathway is a characteristic of up to 70% of breast cancers of all molecular breast cancer subtypes, i.e., Luminal A, Luminal B, Her2 (ErbB2)-enriched, as well as basal-like, triple-negative cancers [40].